Each tablet contains Clopidogrel Bisulfate USP Equivalent to Clopidogrel 75 mg.
Pharmacology: Pharmacokinetics: Clopidogrel is rapidly but incompletely absorbed following oral administration; absorption appears to be about 50%. It is a prodrug and is extensively metabolised in the liver following absorption, mainly to the inactive carboxylic acid derivative. The active metabolite appears to be a thiol derivative but has not been identified in plasma.
Clopidogrel and the carboxylic acid derivative are highly protein bound.
Clopidogrel and its metabolites are excreted about equally in urine and in feces.
Clopidogrel is an antiplatelet drug used in thromboembolic disorders such as myocardial infarction, peripheral arterial disease and stroke. It is given prophylactically as an alternative to aspirin in patients at risk of intermittent claudication and ischaemic heart disease. It is also used as an adjunct to aspirin in prevention of subacute stent occlusion intracoronary stenting.
Clopidogrel is given by mouth as the bisulfate, but doses are expressed in terms of the base; the usual dose is 75 mg once daily.
Or as prescribed by a physician.
Clopidogrel should not be administered to patients with hematopoietic disorders such as neutropenia or thrombocytopenia, haemorrhagic diathesis or other hemorrhagic disorders associated with a prolonged bleeding time, or conditions with an increased risk of bleeding such as gastrointestinal ulcers, acute cerebral hemorrhage or severe liver dysfunction. Full blood counts should be performed before starting treatment and every 2 weeks during the first 3 months of therapy.
Gastrointestinal disturbances and skin rashes are the most common reported side-effects associated with clopidogrel therapy. Blood dyscrasias, including neutropenia and thromboetic thrombocytopenic purpura, and haemorrhagic disorders also occurred. There have been reports of hepatitis and cholestatic jaundice. Blood-lipid concentrations may increase during long term therapy.
Clopidogrel should be used with caution in patients receiving other drugs, such as anticoagulants and antiplatelets, that increases the risk of bleeding. It may inhibit the metabolism of the other drugs that are metabolised in the liver. The clearance may be reduced by concomitant Cimetidine therapy. Corticosteroids may antagonize the effect of Clopidogrel on bleeding time.
Store at a temperature not exceeding 30°C. Protect from light.
B01AC04 - clopidogrel ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.